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Abstract
Objectives The purpose of this study was to evaluate if
positron emission tomography (PET)/magnetic resonance
imaging (MRI) with just one gradient echo sequence using
the body coil is diagnostically sufficient compared with a
standard, low-dose non-contrast-enhanced PET/computed
tomography (CT) concerning overall diagnostic accuracy,
lesion detectability, size and conspicuity evaluation.
Methods and materials Sixty-three patients (mean age
58 years, range 19–86 years; 23 women, 40 men) referred
for either staging or restaging/follow-up of various malignant
tumours (malignant melanoma, lung cancer, breast cancer,
Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, CUP,
gynaecology tumours, pleural mesothelioma, oesophageal
cancer, colorectal cancer, stomach cancer) were prospectively
included. Imaging was conducted using a tri-modality
PET/CT-MR set-up (full ring, time-of-flight Discovery
PET/CT 690, 3 T Discovery MR 750, both GE Healthcare,
Waukesha, WI). All patients were positioned on a dedicated
PET/CT- and MR-compatible examination table, allowing for
patient transport from the MR system to the PET/CT without
patient movement. In accordance with RECIST 1.1 criteria,
measurements of the maximum lesion diameters on CT and
MR images were obtained. In lymph nodes, the short axis was
measured. A four-point scale was used for assessment of
lesion conspicuity: 1 (>25 % of lesion borders definable), 2
(25–50 %), 3 (50–75 %) and 4 (>75 %). For each lesion the
corresponding anatomical structure was noted based on ana-
tomical information of the spatially co-registered PET/CTand
PET/MRI image sections. Additionally, lesions were divided
into three categories: “tumour mass”, “lymph nodes” and
“lesions”. Differences in overall lesion detectability and con-
spicuity in PET/CT and PET/MRI, as well as differences in
detectability based on the localisation and lesion type, were
analysed by Wilcoxon signed rank test.
Results A total of 126 PET-positive lesions were evaluated.
Overall, no statistically significant superiority of PET/CT
over PET/MRI or vice versa in terms of lesion conspicuity
was found (p=0.095; mean score CT 2.93, mean score MRI
2.75). A statistically significant superiority concerning con-
spicuity of PET/CT over PET/MRI was found in pulmonary
lesions (p=0.016). Additionally, a statistically significant
superiority of PET/CT over PET/MRI in “lymph nodes”
regarding lesion conspicuity was also found (p=0.033). A
higher mean score concerning bone lesions were found for
PET/CTcompared with PET/MRI; however, these differences
did not achieve statistical significance.
Conclusion Overall, PET/MRI with body coil acquisition
does not match entirely the diagnostic accuracy of standard
low-dose PET/CT. Thus, it might only serve as a back-up
solution in very few patients. Overall, more time needs to be
invested on the MR imaging part (higher matrix, more
breath-holds, additional surface coil acquired sequences) to
match up with the standard low-dose PET/CT.
Main Messages
• Evaluation of whether PET/MRI with one sequence using
body coil is diagnostically sufficient compared with PET/CT
• PET/MRI with body coil does not match entirely the
diagnostic accuracy of standard low-dose PET/CT
• PET/MRI might only serve as a backup solution in
patients.
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Introduction
Integrated positron emission tomography (PET)/computed to-
mography (CT) has evolved into a mainstay of oncological
imaging over the last decade [1–5]. The interest to integrate
PET with magnetic resonance imaging (MRI) in a similar way
has increased recently and simultaneous PET/MRI or sequential
PET/CT-MR systems potentially open new perspectives in clin-
ical molecular imaging [6–13]. Superior soft tissue contrast of
MRI compared with CTand less radiation exposure are themost
obvious advantages of a simultaneous system. Other potential
improvements—not yet proven in clinical trials—of PET/MRI
over co-registered PET/CT includes the detection and
localisation of liver metastases, detection and characterisation
of gynaecological tumours as well as head and neck cancers [6,
7, 14]. Vice versa, PET/CT still have advantages in lesion
detection and characterisation, for example, in bone lesions
and lung tumours [15–17]. Several technical and clinical issues
(e.g. sequence selection, clinical indications and workflow con-
siderations, to name a few) have to be addressed before PET/CT
can potentially be replaced by PET/MRI. Clinical MR imaging
in oncology indications is mainly focused on one body region,
while PET/CT imaging is usually performed as whole-body
imaging. However, since PET/MRI should measure up to
PET/CT, several controversies are currently being debated in
the literature concerning the clinical imaging protocol [14, 18,
19]. In clinical routine,MRI is usually done with surface coils to
achieve sufficient resolution as well as signal intensity. Also, CT
imaging is usually done with sufficient dose and contrast media.
However, those rules partly do not apply for PET/CT imaging,
since the PET component already provides the main character-
istics of the evaluated lesion. Therefore, even if in normal
clinical routine body-coil imaging alone is certainly not ade-
quate to achieve sufficient image quality, there might be a
clinical situation in multi-modality imaging where it might be
desirable to have a quick whole-body PET/MRI—e.g. in pa-
tients with severe claustrophobia, in patients who had to be
imaged as quickly as possible based on medical conditions or
in cases of technical (surface-coil) failure. In those situations, it
might be enough to have PET/MRI—even only with a body
coil—to achieve a sufficient diagnosis.
Therefore, the purpose of our study was to evaluate if
PET/MRI imaging with just one sequence using a body
coil—which is the minimum acquired sequence because it is
needed for MRAC—can measure up to a standard, low-dose
non-contrast-enhanced PET/CT in the above-mentioned clinical
scenarios.
Materials and methods
Patient population
A total of 63 adult patients (mean age 58 years, range 19–
86 years; 23 women, 40 men) referred for either staging or
restaging/follow-up of various malignant tumours participated
in this prospective study (Table 1). Inclusion criteria were a
clinically indicated whole-body 18F-fluorodeoxyglucose (18F-
FDG)-PET/CT and willingness to participate in the additional
MRI with subsequent shuttle procedure. Exclusion criteria
were unwillingness to undergo an additional MR exam, claus-
trophobia, MR incompatible implanted medical devices (e.g.
cardiac pacemakers, insulin pumps, neurostimulators, cochle-
ar implants), possible metallic fragments in the body or a body
habitus that did not fit into the MR gantry together with the
mounted shuttle board. This study was approved by the local
ethical committee and written informed consent was obtained
from all patients prior to the investigation.
Imaging modalities
Sequential PET/CT and MR imaging were performed on a
tri-modality PET/CT + MR setup (full ring, time-of-flight
Discovery PET/CT 690, 3 T Discovery MR 750; both GE
Healthcare, Waukesha, WI). All patients were positioned on
a dedicated PET/CT- and MR-compatible examination
table, allowing for patient transport from the MR system
to the PET/CT and placement/removal of dedicated
radiofrequency (RF) coils without repositioning/movement
of the patient [20].
PET/CT
Patients fasted for at least 4 h prior to injection of a standard
dose with a mean activity of 334 MBq of 18F-FDG. After a
standardised uptake time of 60 min (range 52–74 min)
unenhanced low dose CT and PET emission data were
acquired from the mid-thigh to the vertex of the skull. CT
data were acquired with automated dose modulation (max-
imal 100 mA) 120 kVp, a collimation of 64×0.625 mm, a
measured field of view (FOV) of 50 cm, a noise index of
20 %, reconstructed to images of 0.625-mm transverse pixel
size and 3.75-mm slice thickness. PET data was acquired in
3D mode with scan duration of 2 min per bed position and
an axial FOV of 153 mm. The emission data was corrected
in a standardised way (random, scatter and attenuation) and
iteratively reconstructed (matrix size, 256×256, Fourier
rebinning [VIP mode], VUE Point FX [3D] with 3 itera-
tions, 18 subsets). Patients were already positioned on the
dedicated shuttle board within the PET/CT-system.
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Table 1 Patient’s characteristics and disease distribution
Patient no. Sex Age Type of malignancy No. of positive PET findings No. of lesions
1 M 36 Malignant neoplasm of oral cavity None 0
2 F 67 Non-Hodgkin’s lymphoma None 0
3 M 75 Oesophageal cancer Lung (1), pleura (1) 2
4 M 58 Malignant melanoma Lymph node (6), adrenal gland (2), liver (1), bone (1), lung (1) 11
5 M 76 Pleural mesothelioma Pleura (3) 3
6 F 64 Non-Hodgkin’s lymphoma Lymph node (2) 2
7 M 72 Malignant melanoma None 0
8 M 75 Lung cancer Lymph node (2) 2
9 M 53 Oesophageal cancer Lymph node (2) 2
10 F 40 Gynaecology tumour Small bowl (1) 1
11 M 42 Stomach cancer None 0
12 F 74 Breast cancer Pleura (1), chest wall (1) 2
13 M 52 Malignant melanoma None 0
14 M 78 Malignant melanoma Lymph node (2) 2
15 F 72 Gynaecology tumour Lymph node (1), vagina (1) 3
16 M 55 Malignant neoplasm of tongue Tongue (1), lymph node (1), bone (1) 3
17 M 80 Malignant neoplasm of hypopharynx Lymph node (2), lung (2) 4
18 M 47 Cancer of unknown origin None 0
19 M 59 Malignant melanoma None 0
20 M 50 Colorectal cancer None 0
21 F 86 Cancer of unknown origin Lymph node (5), sigmoid colon (1), tonsil (1) 7
22 F 56 Malignant neoplasm of thymus Lymph node (2), thymus (1) 3
23 M 67 Pleural mesothelioma Lymph node (1), bone (1), pleura (1) 3
24 M 67 Hodgkin’s lymphoma Tonsil (1), sigmoid colon (1) 2
25 M 66 Malignant melanoma Bone (1) 1
26 M 34 Lung cancer Lung (2) 2
27 M 50 Hodgkin’s lymphoma Lymph node (1), stomach (1) 2
28 M 38 Hodgkin’s lymphoma Lymph node (2) 2
29 F 57 Cancer of unknown origin Vagina (1) 1
30 M 86 Oesophageal cancer None 0
31 F 40 Breast cancer Breast (1) 1
32 M 75 Pleural mesothelioma Lymph node (1), mesenterium (1), abdominal wall (1) 3
33 M 19 Hodgkin’s lymphoma Colon (1) 1
34 M 69 Malignant melanoma Cutaneous (1) 1
35 F 53 Colorectal cancer Liver (2), lymph node (1), lung (1) 4
36 M 44 Lung cancer Lymph node (2), lung (1) 3
37 M 69 Malignant melanoma Lymph node (1) 1
38 F 51 Breast cancer Lymph node (3), bone (2) 5
39 M 70 Stomach cancer Bone (2), prostate (1), liver (1), stomach (1), lymph node (1) 6
40 F 61 Lung cancer Lung (1), lymph node (1) 2
41 F 60 Lung cancer None 0
42 W 50 Gynaecology tumour Lymph node (2) 2
43 M 61 Malignant melanoma None 0
44 F 38 Breast cancer Lymph node (1) 1
45 M 41 Non-Hodgkin’s lymphoma Lymph node (4) 4
46 M 69 Lung cancer Lung (1) 1
47 M 61 Lung cancer Lung (1), adrenal gland (1), bone (1) 3
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MR imaging
After the PET/CT, patients were transferred via a dedicated
shuttle system to theMRI while remaining on the shuttle board.
A whole-body multi-section MR scan was acquired. An axial
two-point Dixon-based T1-weighted 3D gradient echo se-
quence (LAVA flex) was acquired and fat-suppressed images
were reconstructed for all stations. Additionally, images with-
out fat suppression as well as in-phase and opposed-phase
images were reconstructed. All FOVs were acquired axially
for routine clinical evaluation (TE/TR 1.8/3.9 ms, slice thick-
ness 6.8 mm, total MR acquisition time 128–144 s). Coverage
was 25 cm, imaging was done in breath-hold for breathing-
sensitive areas (thorax/abdomen). No other planes of orienta-
tion or sequences were acquired for this study. No contrast
medium was applied during MRI. No dedicated RF coils were
positioned on the patient to perform body coil imaging only.
Image processing
The acquired PET, CT and MR images were sent to a
dedicated review workstation (Advantage Workstation, Ver-
sion 4.6; GE Healthcare, Milwaukee, WI), which allows for
simultaneous review of the PET, CT, MRI as well as
PET/CT and PET/MRI images. The workstation layout al-
lows for dedicated fused views of all modalities side-by-
side.
Image analysis
Images were analysed by one dual-board-certified
radiologist/nuclear medicine physician with 6 years of
experience and one board-certified radiologist with 7 years of
experience. Reading of PET/CT and PET/MRI scans were
done independently and blinded to the results of the other
reader. First, the PET/CT exams and the PET/MRI exams
were evaluated for the presence of PET-positive and PET-
negative (suspicious for tumour) lesions. Lesions were con-
sidered PET-positive if their standardised uptake value (SUV;
corrected for body weight and height) was distinctively higher
than the surrounding background activity. The threshold value
of the maximum standardised uptake value (SUVmax) was
manually adjusted for each lesion. By this adjustment, the
volume of interest (VOI) delineates only the borders of the
tumour based on its PET-activity. Up to 11 PET-positive
lesions were evaluated per patient with a maximum of two
lesions per single organ/compartment (see below). In patients
with multiple lesions in the same organ (e.g. disseminated
liver metastases) the largest lesions and lesions that were
clearly distinguishable from each other were selected for
analysis. Lesion detection and evaluation were done indepen-
dently by each reviewer. After full and independent evaluation
of all lesions in PET/CTand in PET/MRI, lesion selection was
compared between both readers. In case of differently chosen
lesions on PET/CT or PET/MRI, both readers agreed upon
which lesion finally were taken into the analysis.
The scanned volume (vertex of the skull to mid-thigh)
was divided into eight different compartments or regions
(cervical, axillary, mediastinum, pulmonary, liver, other gas-
trointestinal organs, retroperitoneal space and bone).
In accordance with RECIST 1.1 criteria, measurements
of the maximum lesion diameters on PET/CT and PET/MR
images were obtained. In lymph nodes, the short axis was
measured. PET-positive lesions that were morphologically
Table 1 (continued)
Patient no. Sex Age Type of malignancy No. of positive PET findings No. of lesions
48 M 72 Lung cancer Lymph node (3), lung (1), liver (1) 5
49 F 30 Non-Hodgkin’s lymphoma Lymph node (1) 1
50 M 64 Hodgkin’s lymphoma Parotid gland (1) 1
51 F 32 Gynaecology tumour None 0
52 F 59 Breast cancer Lymph node (2), breast (1), thyroid gland (1) 4
53 M 56 Cancer of unknown origin None 0
54 M 71 Malignant melanoma Lymph node (2), mediastinum (2) 4
55 F 46 Breast cancer Bone (2), breast (1) 3
56 M 64 Malignant neoplasm of larynx None 0
57 M 61 Lung cancer Lung (1) 1
58 M 30 Cancer of unknown origin None 0
59 F 49 Breast cancer None 0
60 F 47 Thyroid cancer Lung (2) 2
61 F 45 Malignant neoplasm of peritoneum Pleura (1), mesenterium (1) pelvic (1) 3
62 F 59 Malignant melanoma None 0
63 M 68 Non-Hodgkin’s lymphoma Lymph node (4) 4
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invisible on CT or MRI could not be measured in that
particular modality and were noted as “not measurable”. A
four-point scale was used for assessment of lesion conspi-
cuity: 1 (less than 25 % of lesion borders definable) = not
detectable or poorly delimitable, 2 (25–50 % of borders
definable) = moderately delimitable, 3 (50–75 % of borders
definable) = well delimitable, 4 (more than 75 % of lesion
borders definable) = excellently delimitable. For each lesion
the corresponding anatomical structure was noted based on
anatomical information of the spatially co-registered
PET/CT and PET/MR image sections. Additionally, lesions
were divided into three categories: “tumour mass”, “lymph
nodes” and “lesions”. The first category was used if a mass
was found within an organ (e.g. hypodense mass within the
liver) exhibiting space-occupying characteristics like ex-
ceeding the organ surface/capsule or which exceeded organ
specific boundaries within the organ itself (e.g. liver seg-
ments). The second category was used for lumps/tumours
which were located in the lymphatic network of the evalu-
ated compartment (e.g. retroperitoneal lymph nodes). The
last category was used for all other lesions without mass
characteristics, e.g. sclerotic or lytic bone lesions.
Statistical analysis
All statistical tests were performed using IBM SPSS Statistics
20 (SPSS, Chicago, IL, USA). A p value of <0.05 was
considered statistically significant. Differences between lesion
size and conspicuity in PET/CT and PET/MRI were analysed
by Wilcoxon signed ranks test. Analyses were performed for
the above-mentioned three categories of lesions as well as for
the above-mentioned eight body portions. A minimum of
Table 2 Conspicuity and lesion size in CT and MRI
Conspicuity score CT MRI
Frequency Percent Frequency Percent
1 17 13.5 27 21.4
2 29 23.0 23 18.3
3 26 20.6 30 23.8
4 54 42.9 46 36.5
Total 126 100.0 126 100.0
Mean score 2.93 2.75
Fig. 1 Comparison of PET/CT
and PET/MRI of a patient with
diffuse metastasis of malignant
melanoma. Axial CT (a) and
MRI (b) images show a large
lymph node metastasis in the
right groin (arrowhead) with
corresponding 18F-FDG activity
in axial PET/CT (c) and PET/
MRI (d). In this patient, lesion
conspicuity was rated as
“excellently delimitable” (score
4) for both CT and MRI, no
difference in image quality was
observed. Note the non-avid
seroma in the left groin (*)
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seven lesions per body portion/compartment was required for
statistical analysis to achieve equal distributions for all cate-
gories analysed.
Results
The primary malignancy of 63 examined patients were ma-
lignant melanoma (n=11; 17 %), lung cancer (n=9; 14 %),
breast cancer (n=7; 11 %), Hodgkin’s lymphoma (n=6; 9 %),
cancer of unknown origin “cup” (n=5; 8 %), non-Hodgkin’s
lymphoma (n=4; 6 %), gynaecology tumours (n=4; 6 %),
pleural mesothelioma (n=3; 5 %), oesophageal cancer (n=3;
5 %), colorectal cancer (n=2; 3 %), stomach cancer (n=2;
3 %) as well as seven individual cases of primary tumours
located in the thymus, oral cavity, tongue, hypopharynx,
larynx, thyroid gland and retroperitoneum (each 1.8 %).
A total of 17 patients were excluded from further eval-
uation due to the absence of suspicious, tumorous le-
sions. Forty-six of the 63 patients examined with
sequential PET/CT and MRI presented at least one le-
sion. A total of 126 lesions were evaluated (Table 1).
Overall lesion detection, conspicuity and lesion size
Wilcoxon signed ranks test yielded overall no statistically
significant superiority of PET/CT over PET/MR or vice
versa in terms of lesion conspicuity (p=0.095; mean score
PET/CT 2.93, mean score PET/MRI 2.75) (Table 2).
A total of 101 lesions were visible and measurable both on
PET/CT and PET/MRI. Seventeen (16.8 %) lesions were
visible only on PET/CT, six (6 %) were visible only on
PET/MRI and two (1.9 %) were visible neither on CT nor
on MRI (only PET-positive without a morphological corre-
late) (Figs. 1, 2, and 3). Seven of the 17 lesions visible only on
PET/CTwere lymph nodes (two perigastic, two cervical, two
in the mediastinum and one single lymph node adjacent to the
internal mammary artery), five were bone lesions, four were
located in the lungs, and one lesion each in the thyroid and in
the vagina were missed on PET/MRI. Three of the six lesions
visible only on PET/MRI were mediastinal lymph nodes as
well as one liver lesion, one thyroid lesion and one chest wall
lesion. One PET-positive lesion in the breast and one in the
colon were only visible on PET images without a morpholog-
ical correlate on PET/CT and PET/MRI. Wilcoxon signed
Fig. 2 Comparison of PET/CT
and PET/MRI of a patient with
lung cancer with
intrapulmonary metastasis
showing partial superiority of
CT versus MRI. CT (a) and
PET/CT (c) show two small,
FDG-avid lung metastases
(arrows), a large, left-sided,
polylobular pleural metastatic
tumour (*) and a partially/
centrally necrotic metastatic
tumour within the right lung
(arrowhead). The right-sided
necrotic lesion is only partly
visible on the MRI (b) and
PET/MRI (d)
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ranks test of the 101 visible lesions yielded no statistically
relevant difference in terms of lesion size between CT and
MRI (p=0.251). The mean diameter was 20.21 mm (range 4–
80 mm) for CT and 19.94 mm (range 4–82 mm) for MRI.
Location (organ) based comparison of conspicuity and size
Regarding lesion conspicuity, Wilcoxon signed ranks test
yielded a statistically significant superiority of PET/CT over
PET/MRI in pulmonary lesions (p=0.016). For all other
organs/anatomical structures, no significant differences
were found between PET/CT and PET/MRI concerning both
lesion conspicuity and lesion size (Table 3).
Comparison of lesion conspicuity and size regarding lesion
type
Thirty-seven out if the 126 PET-positive findings were
characterised as “tumour mass”, 57 as “lymph node” and
17 as “lesion” (overall 111 PET-positive findings evaluated,
not all PET-positive findings visible on PET/CT and/or
PET/MRI, see above). The remaining findings (15 lesions,
focal FDG-uptake without morphological correlate [see
above], pulmonary nodules, abscess) did not fit in the here
evaluated categories. Furthermore, the quantity of those lesions
were below seven (see “Materials and methods”) and were
therefore not further considered in this evaluation (Table 4).
Wilcoxon signed ranks test yielded a statistically signifi-
cant superiority of PET/CTover PET/MRI for “lymph nodes”
regarding lesion conspicuity (p=0.033). No statistically sig-
nificant difference was found in lesion conspicuity for “tu-
mour mass” (p=0.176) and for “lesion” (p=0.700). Also no
statistically significant difference was found in lesion diameter
regarding all three lesion types (p=0.124 for “tumour mass”;
p=0.213 for “lymph node”; p=0.234 for “lesion”). One no-
ticeable difference was found for bone lesions (see also
Table 3). There was a higher mean score in PET/CT detected
for bone lesions compared with PET/MRI. However, despite
this demonstrative finding, no statistical significance could be
established for this sub-category of “lesions”.
Discussion
The purpose of this study was to investigate the diagnostic
utility of a PET/MRI with only an axial T1-weighted fast
Fig. 3 Comparison of PET/CT
and PET/MRI of a patient
showing superiority of MRI
versus CT. Axial MRI (b) and
axial PET/MRI (d) images
show a small FDG-avid liver
metastasis in segment VII
(arrowhead) adjacent to the
liver vein. The lesion is only
detectable in co-registered PET/
CT images (c) but undetectable
on unenhanced low-dose CT
axial images (a)
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gradient echo sequence using a body coil (which is the basic
sequence needed for MR-based attenuation correction
[MRAC]) compared with standard low-dose PET/CT. Gener-
ally, no significant differences were found concerning lesion
size and conspicuity. However, there was an advantage of
PET/CT over PET/MRI concerning detection of lung lesions
and bone lesions, as well as in lymph node conspicuity.
Overall, PET/MRI with just one sequence using a body coil
does not match entirely the diagnostic accuracy of standard
low-dose PET/CT and thus, might only serve as a back-up
solution in very limited cases.
For our study, we used a tri-modality PET/CT-MRI system.
In such a setting, the PET/CT or the MRI examination is done
first and the other imaging modality follows directly after using
the described dedicated shuttle solution [20]. This approach
certainly is—like in PET/CT—a sequential approach but all
acquired imagingmodalities can be exactly co-registered based
on the explained shuttle procedure. The goal of this study was
to compare PET/CT and PET/MRI, and thus simultaneity of
PET/MRI was not needed. Several controversies inMRI-based
attenuation still have to be considered—e.g. segmentation of
bone, air and soft tissue, as well as truncation artefacts [2, 21].
Therefore, since CT-based attenuation correction (CTAC)
compared with MRI-based attenuation correction in simulta-
neous approaches is still considered the “gold standard”, it
might be helpful to have such data still available as a back-
up, especially in initial trial periods. During clinical routine, we
still use the CTAC. TheMRAC is evaluated for study purposes
in our setting as well, however, those evaluations were beyond
the scope of this manuscript. Furthermore, there are studies
now indicating that, at least for routine diagnostic purposes
(except for bone lesions), diagnostic differences are minor [22].
Comparison with current literature
Regarding the quantitative analysis of tracer uptake by SUV-
based analysis, partly different SUVs have been observed for
data acquired on the simultaneous PET/MRI compared with
the PET/CT scanner for suspected lesions in other studies [10,
11, 16]. In general, the difference of mean SUVs between
PET/CT and simultaneous PET/MRI can be explained by a
delayed acquisition times after i.v. injection of the 18F-FDG,
partly by tumour biology, by differences in the technological
specifications and data-processing algorithms of the two hy-
brid scanners. Even initially missed lesions on PET/MRI have
been reported; however, those were special cases in tumours
which were not well suited for FDG-based imaging anyway
[10]. In our described sequential set-up, we only have one
measurement of SUV within the PET/CT examination, and
thus no differences in SUV uptake and lesion-to-background
contrast can occur. This way, constant PET volumes can be
achieved for initial measurement and for therapy follow-up
and no different tracer kinetics between the two examinations
have to be considered.
Overall, lesion conspicuity was not statistically significant
different in both PET/CT and PET/MRI. However, lung le-
sions and bone lesions were significantly better detectable and
definable on PET/CT. This is in line with previous results
from Eiber et al. [11], where PET/CT tended to be superior
concerning delineation in lung lesions. The reasons for those
Table 3 Location/organ based comparison of conspicuity and size
n CT MRI
Mean Range Mean Range
Axilla 8 Score 3.88 3–4 3.88 3–4
Size [mm] 9.36 5–13 9.46 4–14
Cervical 17 Score 2.88 1–4 2.71 1–4
Size [mm] 11.48 0–33 11.31 0–37
GIT + urogenital 10 Score 2.00 1–4 2.40 1–4
Size [mm] 28.22 0–55 25.03 0–48
Iliacal 7 Score 4.00 4–4 3.86 3–4
Size [mm] 13.53 4–22 13.87 4–22
Breast 7 Score 2.57 1–4 1.86 1–3
Size [mm] 7.80 0–16 8.97 0–16
Mediastinum 19 Score 2.68 1–4 2.42 1–4
Size [mm] 20.22 0–72 19.83 0–72
Mesenterium 8 Score 2.88 2–4 2.38 1–4
Size [mm] 23.24 5–80 20.88 0–82
Bone 10 Score 2.80 1–4 2.10 1–4
Size [mm] 15.17 7–13 9.94 0–36
Pleura 7 Score 2.57 2–4 2.71 1–4
Size [mm] 10.06 7–22 12.43 0–23
Lung 15 Score 3.60 2–4 2.67 1–4
Size [mm] 21.48 4–50 20.01 0–50
Retroperitoneum 9 Score 3.67 2–4 3.78 3–4
Size [mm] 27.96 7–80 27.14 7–76
Score conspicuity score; Size a size 0 indicates the lesion is only
detectable on the PET-component, no size measurement possible
Table 4 Comparison of lesion conspicuity and size based on lesion
type
n CT MRI
Mean Range Mean Range
Tumour mass 37 Score 3.08 1–4 2.78 1–4
Size [mm] 22.81 0–55 22.13 0–50
Lymph node 57 Score 3.26 1–4 3.01 1–4
Size [mm] 14.32 0–80 13.81 0–82
Lesion 17 Score 2.29 1–4 2.41 1–4
Size [mm] 14.1 0–31 10.65 0–36
Score conspicuity score; Size a size 0 indicates the lesion is only
detectable on the PET-component, no size measurement possible
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results in PET/CTare certainly the higher speed and resolution
of CTwithin the lungs. Lungs are known to be one of the most
challenging organs in MRI. The reason why our results in
PET/MRI were significantly lower might be the use of a body
coil (the purpose of the study), which inherently has a lower
image quality. In another study it was indicated that the CT
component of the PET/CT actually detects more lesions as
well [17]. However, no evaluation concerning differences in
potentially treatable lung lesions was made. In the studies of
Eiber et al. [11] and Drzezga et al. [10], no significant differ-
ence was found between water-only images and fat-only
images as well as compared with in/opposed-phase images,
which we can confirm in our study. In fact, reconstructed fat-
weighted images were shown to be inferior compared to the
other images. Initial results on PET/MRI in bronchial carci-
noma showed that PET/MRI is feasible and provides in most
patients similar lesion characterisation and tumour stage.
However, the study included only a very small number of
patients, only large tumours and PET/CT still showed better
results concerning the TNM staging in almost one-third of the
patients [16]. Overall there was no statistically significant
difference when evaluating PET-positive lesions based on
the lesion’s type in our study. However, we found significant
differences when evaluation lymph nodes. This is in line with
the previously mentioned studies where PET/CT tended to be
superior in lymph node evaluation as well [11]. One reason
might be that lymph nodes in the axilla and in areas with
sufficient surrounding fatty tissue are easier to detect than
lymph nodes close to vessels like in the retroperitoneal space
or in the periportal region. However, it is slightly surprising
that we found a statistically significant difference, although
we used a higher matrix in PET/MRI (320×256 vs 79×192).
Reasons for that finding might be a different distribution of
lymph in the evaluated compartments and the somewhat
low number of patients and lesions in our as well as in the
aforementioned studies.
Other studies also reported that PET/CT tended to be
superior to PET/MRI in the detection and conspicuity of bone
lesions. Also in our study, there was a higher mean score
found for PET/CT compared with PET/MRI for bone lesions,
but those results did not yield any statistical difference. How-
ever, five bone lesions were detected on PET/CT but not on
PET/MRI. It has already been shown in other studies that the
detection and characterisation of bone lesions by PET/MRI is
challenging, especially in therapy follow-up [15].
One limitation of our study is that histological results as the
“gold standard” of reference were not available for all lesions
evaluated. All patients underwent biopsy during the time
course of their disease for establishment of the primary diag-
nosis, though. Another limitation is the different slice thick-
ness of PET/MRI and PET/CT. But this inherent drawback
was actually part of the study, since the body coil imaging was
specifically evaluated. Basic body coil sequences are needed
for the MRAC in PET/MRI. We investigated an inhomoge-
neous patient population, which can be considered as a draw-
back when drawing conclusions on specific tumour
indications. However, in this way a general overview of such
an evaluation can be provided.
Conclusions
Overall, when comparing standard PET/CT and basic
PET/MRI with body coil acquisition—the basic sequence
needed for the MRAC—PET/MRI does not entirely match
the diagnostic accuracy of standard low-dose PET/CT.
Thus, it might only serve as a back-up solution in very
few patients. One task for the future of PET/MRI therefore
might be the evaluation of how many MRI sequences and
how much information from the MRI is needed (matrix,
breath-holds, different weightings) to match up to a standard
low-dose PET/CT, ideally within the same acquisition time.
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